Abstract
Specific chemical modifications of biological molecules are an efficient way of regulating molecular function, and a plethora of downstream signalling pathways are influenced by the modification of DNA and proteins. Many of the enzymes responsible for regulating protein and DNA modifications are targets of current cancer therapies. RNA epitranscriptomics, the study of RNA modifications, is the new frontier of this arena. Despite being known since the 1970s, eukaryotic RNA modifications were mostly identified on transfer RNA and ribosomal RNA until the last decade, when they have been identified and characterized on mRNA and various non-coding RNAs. Increasing evidence suggests that RNA modification pathways are also misregulated in human cancers and may be ideal targets of cancer therapy. In this Review we highlight the RNA epitranscriptomic pathways implicated in cancer, describing their biological functions and their connections to the disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Roundtree, I. A., Evans, M. E., Pan, T. & He, C. Dynamic RNA modifications in gene expression regulation. Cell 169, 1187–1200 (2017).
Li, S. & Mason, C. E. The pivotal regulatory landscape of RNA modifications. Annu. Rev. Genomics Hum. Genet. 15, 127–150 (2014).
Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28–39 (2009).
Dor, Y. & Cedar, H. Principles of DNA methylation and their implications for biology and medicine. Lancet 392, 777–786 (2018).
Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).
Mohammad, H. P., Barbash, O. & Creasy, C. L. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat. Med. 25, 403–418 (2019).
Gebert, L. F. R. & MacRae, I. J. Regulation of microRNA function in animals. Nat. Rev. Mol. Cell Biol. 20, 21–37 (2019).
Yao, R.-W., Wang, Y. & Chen, L.-L. Cellular functions of long noncoding RNAs. Nat. Cell Biol. 21, 542–551 (2019).
Zhao, B. S., Roundtree, I. A. & He, C. Post-transcriptional gene regulation by mRNA modifications. Nat. Rev. Mol. Cell Biol. 18, 31–42 (2017).
Shelton, S. B., Reinsborough, C. & Xhemalce, B. Who watches the watchmen: roles of RNA modifications in the RNA interference pathway. PLoS Genet. 12, e1006139 (2016).
Esteller, M. & Pandolfi, P. P. The epitranscriptome of noncoding RNAs in cancer. Cancer Discov. 7, 359–368 (2017).
Helm, M. & Motorin, Y. Detecting RNA modifications in the epitranscriptome: predict and validate. Nat. Rev. Genet. 18, 275–291 (2017).
Shubert, C. Epitranscriptomics: RNA revisited. Science 364, 693–695 (2019).
Desrosiers, R., Friderici, K. & Rottman, F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc. Natl Acad. Sci. USA 71, 3971–3975 (1974).
Fazi, F. & Fatica, A. Interplay between N6-methyladenosine (m6A) and non-coding RNAs in cell development and cancer. Front. Cell Dev. Biol. 7, 116 (2019).
Alarcón, C. R., Lee, H., Goodarzi, H., Halberg, N. & Tavazoie, S. F. N6-methyladenosine marks primary microRNAs for processing. Nature 519, 482–485 (2015).
Maden, B. E. H. Identification of the locations of the methyl groups in 18S ribosomal RNA from Xenopus laevis and man. J. Mol. Biol. 189, 681–699 (1986).
Maden, B. E. H. Locations of methyl groups in 28S rRNA of xenopus laevis and man: clustering in the conserved core of molecule. J. Mol. Biol. 201, 289–314 (1988).
Liu, J. et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 10, 93–95 (2014). In this study, the METTL3–METTL14 complex is identified as the main m 6A writer in mammalian cells.
Pendleton, K. E. et al. The U6 snRNA m6A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell 169, 824–835.e14 (2017).
van Tran, N. et al. The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucleic Acids Res. 47, 7719–7733 (2019).
Ma, H. et al. N6-Methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. Nat. Chem. Biol. 15, 88–94 (2019).
Perry, R. P. & Kelley, D. E. Existence of methylated messenger RNA in mouse L cells. Cell 1, 37–42 (1974).
Dominissini, D. et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485, 201–206 (2012). This important study maps for the first time m 6A modifications on the transcriptome, highlighting the importance of this modification for mRNA regulation and starting the new field of epitranscriptomics.
Patil, D. P. et al. m6A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537, 369–373 (2016).
Jia, G. et al. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7, 885–887 (2011). In this study, the first m 6A eraser is identified. This highlights the dynamic nature of this modification on mRNA.
Zheng, G. et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell 49, 18–29 (2013).
Mauer, J. et al. Reversible methylation of m6Am in the 5′ cap controls mRNA stability. Nature 541, 371–375 (2017).
Liao, S., Sun, H. & Xu, C. YTH domain: a family of N6-methyladenosine (m6A) readers. Genomics Proteomics Bioinformatics 16, 99–107 (2018).
Huang, H. et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell Biol. 20, 285–295 (2018).
Alarcón, C. R. et al. HNRNPA2B1 is a mediator of m6A-dependent nuclear RNA processing events. Cell 162, 1299–1308 (2015).
Wu, R. et al. A novel m6A reader Prrc2a controls oligodendroglial specification and myelination. Cell Res. 29, 23–41 (2019).
Wu, B. et al. Molecular basis for the specific and multivariant recognitions of RNA substrates by human hnRNP A2/B1. Nat. Commun. 9, 420 (2018).
Sun, L. et al. RNA structure maps across mammalian cellular compartments. Nat. Struct. Mol. Biol. 26, 322–330 (2019).
Du, H. et al. YTHDF2 destabilizes m6A-containing RNA through direct recruitment of the CCR4–NOT deadenylase complex. Nat. Commun. 7, 12626 (2016).
Wang, X. et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 161, 1388–1399 (2015).
Vu, L. P. et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat. Med. 23, 1369–1376 (2017). In this study, METTL3 is found to increase MYC translation and sustain the growth of AML cells.
Barbieri, I. et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature 552, 126–131 (2017). This study identifies METTL3 as a potential target in AML and identifies a function of this enzyme that is dependent on its recruitment to chromatin.
Weng, H. et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell 22, 191–205.e9 (2018).
Lin, S., Choe, J., Du, P., Triboulet, R. & Gregory, R. I. The m6A methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell 62, 335–345 (2016).
Chen, M. et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 67, 2254–2270 (2018).
Lin, X. et al. RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. Nat. Commun. 10, 2065 (2019).
Ma, J. et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N 6-methyladenosine-dependent primary MicroRNA processing. Hepatology 65, 529–543 (2017).
Liu, J. et al. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat. Cell Biol. 20, 1074–1083 (2018).
Cui, Q. et al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 18, 2622–2634 (2017).
Visvanathan, A. et al. Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance. Oncogene 37, 522–533 (2018).
Li, F. et al. N6-methyladenosine modulates nonsense-mediated mRNA decay in human glioblastoma. Cancer Res. 79, 5785–5798 (2019).
Brown, J. A., Kinzig, C. G., DeGregorio, S. J. & Steitz, J. A. Methyltransferase-like protein 16 binds the 3′-terminal triple helix of MALAT1 long noncoding RNA. Proc. Natl Acad. Sci. USA 113, 14013–14018 (2016).
Sun, Y. & Ma, L. New insights into long non-coding RNA MALAT1 in cancer and metastasis. Cancers 11, E216 (2019).
Iles, M. M. et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat. Genet. 45, 428–432 (2013).
Yang, S. et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat. Commun. 10, 2782 (2019).
Li, Z. et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell 31, 127–141 (2017). This article describes the discovery of the oncogenic function of the m 6A demethylase FTO in AML.
Elkashef, S. M. et al. IDH mutation, competitive inhibition of FTO, and RNA methylation. Cancer Cell 31, 619–620 (2017).
Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
Su, R. et al. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling. Cell 172, 90–105.e23 (2018).
Huang, Y. et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell 35, 677–691.e10 (2019). This article describes the first small-molecule inhibitor of the m 6A pathway, which demonstrates efficacy in mouse models of AML.
Mauer, J. et al. FTO controls reversible m6Am RNA methylation during snRNA biogenesis. Nat. Chem. Biol. 15, 340–347 (2019).
Zhang, S. et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell 31, 591–606.e6 (2017).
Zhang, C. et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc. Natl Acad. Sci. USA 113, E2047–E2056 (2016).
Tanabe, A. et al. RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. Cancer Lett. 376, 34–42 (2016).
Paris, J. et al. Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell 25, 137–148.e6 (2019).
Han, D. et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 566, 270–274 (2019). In this study, YTHDF1 is identified as a critical suppressor of antigen presentation in dendritic cells and its depletion could enhance the effect of immune checkpoint inhibitors in melanoma.
Degrauwe, N., Suvà, M.-L., Janiszewska, M., Riggi, N. & Stamenkovic, I. IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer. Genes. Dev. 30, 2459–2474 (2016).
Weidensdorfer, D. et al. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA 15, 104 (2009).
Müller, S. et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic Acids Res. 47, 375–390 (2019).
Bohnsack, K., Höbartner, C. & Bohnsack, M. Eukaryotic 5-methylcytosine (m5C) RNA methyltransferases: mechanisms, cellular functions, and links to disease. Genes 10, 102 (2019).
Trixl, L. & Lusser, A. The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark. Wiley Interdiscip. Rev. RNA 10, e1510 (2019).
Schosserer, M. et al. Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan. Nat. Commun. 6, 6158 (2015).
Squires, J. E. et al. Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. Nucleic Acids Res. 40, 5023–5033 (2012).
Legrand, C. et al. Statistically robust methylation calling for whole-transcriptome bisulfite sequencing reveals distinct methylation patterns for mouse RNAs. Genome Res. 27, 1589–1596 (2017).
Song, C. X., Yi, C. & He, C. Mapping recently identified nucleotide variants in the genome and transcriptome. Nat. Biotechnol. 30, 1107–1116 (2012).
Huang, T., Chen, W., Liu, J., Gu, N. & Zhang, R. Genome-wide identification of mRNA 5-methylcytosine in mammals. Nat. Struct. Mol. Biol. 26, 230–388 (2019). This study determines the abundance of high-confidence m 5C modification sites within eukaryotic mRNAs.
Yang, X. et al. 5-methylcytosine promotes mRNA export — NSUN2 as the methyltransferase and ALYREF as an m5C reader. Cell Res. 27, 606–625 (2017). In this study, the first function of mRNA m 5C and the first RNA m 5C reader are identified.
Hussain, S. et al. NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs. Cell Rep. 4, 255–261 (2013).
Freeman, J. W. et al. Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase. Cancer Res. 48, 1244–1251 (1988).
Bantis, A. et al. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology 15, 25–31 (2004).
Saijo, Y. et al. Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma. Ann. Oncol. 12, 1121–1125 (2001).
Frye, M. & Watt, F. M. The RNA methyltransferase Misu (NSun2) mediates Myc-induced proliferation and is upregulated in tumors. Curr. Biol. 16, 971–981 (2006). This article describes the discovery of NSUN2 as a MYC target and oncogenic factor.
Li, Y. et al. Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma. Cancer Lett. 430, 57–66 (2018).
Chen, X. et al. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat. Cell Biol. 21, 978–990 (2019).
Campbell, T. M., Castro, M. A. A., de Oliveira, K. G., Ponder, B. A. J. & Meyer, K. B. ERα binding by transcription factors NFIB and YBX1 enables FGFR2 signaling to modulate estrogen responsiveness in breast cancer. Cancer Res. 78, 410–421 (2018).
Yamashita, T., Higashi, M., Momose, S., Morozumi, M. & Tamaru, J.-I. Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. Int. J. Oncol. 51, 579–586 (2017).
Cheng, J. X. et al. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat. Commun. 9, 1163 (2018).
Saikia, M., Fu, Y., Pavon-Eternod, M., He, C. & Pan, T. Genome-wide analysis of N1-methyl-adenosine modification in human tRNAs. RNA 16, 1317–1327 (2010).
Sloan, K. E. et al. Tuning the ribosome: the influence of rRNA modification on eukaryotic ribosome biogenesis and function. RNA Biol. 14, 1138–1152 (2017).
Safra, M. et al. The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature 551, 251–255 (2017). This study presents the genome-wide mapping of m 1A, showing limited abundance of this modification on mRNA.
Dominissini, D. et al. The dynamic N1-methyladenosine methylome in eukaryotic messenger RNA. Nature 530, 441–446 (2016). This study presents the genome-wide mapping of m 1A in mammalian cells, showing specific topology and association with high translation levels.
Zhou, H. et al. Evolution of a reverse transcriptase to map N1-methyladenosine in human messenger RNA. Nat. Methods 16, 1281–1288 (2019). This study through the development of a new technique to detect m 1A determines the topology of this modification on eukaryotic mRNAs.
Dai, X., Wang, T., Gonzalez, G. & Wang, Y. Identification of YTH domain-containing proteins as the readers for N 1-methyladenosine in RNA. Anal. Chem. 90, 6380–6384 (2018).
Chen, Z. et al. Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res. 47, 2533–2545 (2019).
Liu, F. et al. ALKBH1-mediated trna demethylation regulates translation. Cell 167, 816–828.e16 (2016).
Woo, H.-H. & Chambers, S. K. Human ALKBH3-induced m1A demethylation increases the CSF-1 mRNA stability in breast and ovarian cancer cells. Biochim. Biophys. Acta Gene Regul. Mech. 1862, 35–46 (2019).
Konishi, N. et al. High expression of a new marker PCA-1 in human prostate carcinoma. Clin. Cancer Res. 11, 5090–5097 (2005).
Nakao, S. et al. Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs. Bioorg. Med. Chem. Lett. 24, 1071–1074 (2014).
Duncan, T. et al. Reversal of DNA alkylation damage by two human dioxygenases. Proc. Natl Acad. Sci. USA 99, 16660–16665 (2002).
Ramanathan, A., Robb, G. B. & Chan, S.-H. mRNA capping: biological functions and applications. Nucleic Acids Res. 44, 7511–7526 (2016).
Tomikawa, C. 7-Methylguanosine modifications in transfer RNA (tRNA). Int. J. Mol. Sci. 19, E4080 (2018).
Pandolfini, L. et al. METTL1 promotes let-7 microRNA processing via m7G methylation. Mol. Cell 74, 1278–1290.e9 (2019). In this study, internal m 7G is identified on mature and pre-miRNAs, including let-7, where it is required for pre-let-7 processing.
Zhang, L. S. et al. Transcriptome-wide mapping of internal N7-methylguanosine methylome in mammalian mRNA. Mol. Cell 74, 1304–1316.e8 (2019). This article identifies internal m 7G on mRNA and describes the transcriptome-wide mapping of the modification.
Alexandrov, A., Martzen, M. R. & Phizicky, E. M. Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA. RNA 8, 1253–1266 (2002).
Haag, S., Kretschmer, J. & Bohnsack, M. T. WBSCR22/Merm1 is required for late nuclear pre-ribosomal RNA processing and mediates N7-methylation of G1639 in human 18S rRNA. RNA 21, 180–187 (2015).
Malbec, L. et al. Dynamic methylome of internal mRNA N7-methylguanosine and its regulatory role in translation. Cell Res. 29, 927–941 (2019).
Cartlidge, R. A. et al. The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK in vitro and in cells. EMBO J. 24, 1696–1705 (2005).
Ping, Y. et al. Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data. Nucleic Acids Res. 43, 1997–2007 (2015).
Tian, Q.-H. et al. METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN. J. Mol. Med. 97, 1535–1545 (2019).
Okamoto, M. et al. tRNA modifying enzymes, NSUN2 and METTL1, determine sensitivity to 5-fluorouracil in HeLa cells. PLoS Genet. 10, e1004639 (2014).
Gustavsson, M. & Ronne, H. Evidence that tRNA modifying enzymes are important in vivo targets for 5-fluorouracil in yeast. RNA 14, 666–674 (2008).
Tsukamoto, T., Shibagaki, Y., Niikura, Y. & Mizumoto, K. Cloning and characterization of three human cDNAs encoding mRNA (guanine-7-)-methyltransferase, an mRNA cap methylase. Biochem. Biophys. Res. Commun. 251, 27–34 (1998).
Posternak, V., Ung, M. H., Cheng, C. & Cole, M. D. MYC mediates mRNA cap methylation of canonical Wnt/β-catenin signaling transcripts by recruiting CDK7 and RNA methyltransferase. Mol. Cancer Res. 15, 213–224 (2017).
Franke, J., Gehlen, J. & Ehrenhofer-Murray, A. E. Hypermethylation of yeast telomerase RNA by the snRNA and snoRNA methyltransferase Tgs1. J. Cell Sci. 121, 3553–3560 (2008).
Shelton, S. B. et al. Crosstalk between the RNA methylation and histone-binding activities of MePCE regulates P-TEFb activation on chromatin. Cell Rep. 22, 1374–1383 (2018).
Singh, R. & Reddy, R. Gamma-monomethyl phosphate: a cap structure in spliceosomal U6 small nuclear RNA. Proc. Natl Acad. Sci. USA 86, 8280–8283 (1989).
Xhemalce, B., Robson, S. C. & Kouzarides, T. Human RNA methyltransferase BCDIN3D regulates microRNA processing. Cell 151, 278–288 (2012).
Martinez, A. et al. Human BCDIN3D monomethylates cytoplasmic histidine transfer RNA. Nucleic Acids Res. 45, 5423–5436 (2017).
Davis, F. F. & Allen, F. W. Ribonucleic acids from yeast which contain a fifth nucleotide. J. Biol. Chem. 227, 907–915 (1957).
Penzo, M., Guerrieri, A. N., Zacchini, F., Treré, D. & Montanaro, L. RNA pseudouridylation in physiology and medicine: for better and for worse. Genes 8, E301 (2017).
Carlile, T. M. et al. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature 515, 143–146 (2014).
Schwartz, S. et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell 159, 148–162 (2014).
Li, X. et al. Chemical pulldown reveals dynamic pseudouridylation of the mammalian transcriptome. Nat. Chem. Biol. 11, 592–597 (2015). This article describes the transcriptome-wide mapping of pseudouridines in human cells.
Penzo, M. & Montanaro, L. Turning uridines around: role of rRNA pseudouridylation in ribosome biogenesis and ribosomal function. Biomolecules 8, E38 (2018).
Bohnsack, M. T. & Sloan, K. E. Modifications in small nuclear RNAs and their roles in spliceosome assembly and function. Biol. Chem. 399, 1265–1276 (2018).
Chen, J.-L., Opperman, K. K. & Greider, C. W. A critical stem-loop structure in the CR4-CR5 domain of mammalian telomerase RNA. Nucleic Acids Res. 30, 592–597 (2002).
Carlile, T. M. et al. mRNA structure determines modification by pseudouridine synthase 1. Nat. Chem. Biol. 15, 966–974 (2019).
Zhao, X. et al. Regulation of nuclear receptor activity by a pseudouridine synthase through posttranscriptional modification of steroid receptor RNA activator. Mol. Cell 15, 549–558 (2004).
Jana, S., Hsieh, A. C. & Gupta, R. Reciprocal amplification of caspase-3 activity by nuclear export of a putative human RNA-modifying protein, PUS10 during TRAIL-induced apoptosis. Cell Death Dis. 8, e3093–e3093 (2017).
Heiss, N. S. et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19, 32–38 (1998).
Ruggero, D. et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 299, 259–262 (2003). This study characterizes DKC1 as a tumour suppressor in a mouse model of dyskeratosis congenita, showing that the oncogenic effect of DKC1 loss-of-function mutations is caused by a lack of pseudouridylation of rRNA.
Montanaro, L. et al. Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res. 70, 4767–4777 (2010).
Sieron, P. et al. DKC1 overexpression associated with prostate cancer progression. Br. J. Cancer 101, 1410 (2009).
Penzo, M. et al. Dyskerin and TERC expression may condition survival in lung cancer patients. Oncotarget 6, 21755–21760 (2015).
Menezes, M. R., Balzeau, J. & Hagan, J. P. 3′ RNA uridylation in epitranscriptomics, gene regulation, and disease. Front. Mol. Biosci. 5, 61 (2018).
Martin, G. & Keller, W. RNA-specific ribonucleotidyl transferases. RNA 13, 1834–1849 (2007).
Yu, C. et al. Star-PAP, a poly(A) polymerase, functions as a tumor suppressor in an orthotopic human breast cancer model. Cell Death Dis. 8, e2582–e2582 (2017).
Zhu, D., Lou, Y., He, Z. & Ji, M. Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a. Tumor Biol. 35, 11829–11835 (2014).
Lim, J. et al. Uridylation by TUT4 and TUT7 marks mRNA for degradation. Cell 159, 1365–1376 (2014).
Heo, I. et al. Mono-uridylation of pre-microRNA as a key step in the biogenesis of group II let-7 microRNAs. Cell 151, 521–532 (2012).
Thornton, J. E., Chang, H.-M., Piskounova, E. & Gregory, R. I. Lin28-mediated control of let-7 microRNA expression by alternative TUTases Zcchc11 (TUT4) and Zcchc6 (TUT7). RNA 18, 1875–1885 (2012). In this study, the LIN28-dependent uridylation of let-7 mediated by TUT4 and TUT7 and its effect on let-7 expression levels is discovered.
Wei, T. & Zhao, W.-X. The Wnt-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. Artic. J. Cell Sci. 126, 2877–2889 (2013).
Alajez, N. M. et al. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget 3, 1641–1652 (2012).
Balzeau, J., Menezes, M. R., Cao, S. & Hagan, J. P. The LIN28/let-7 pathway in cancer. Front. Genet. 8, 31 (2017).
Lin, S. & Gregory, R. I. Identification of small molecule inhibitors of Zcchc11 TUTase activity. RNA Biol. 12, 792–800 (2015).
Chang, H.-M., Triboulet, R., Thornton, J. E. & Gregory, R. I. A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. Nature 497, 244–248 (2013).
Astuti, D. et al. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat. Genet. 44, 277–284 (2012).
Ustianenko, D. et al. Mammalian DIS3L2 exoribonuclease targets the uridylated precursors of let-7 miRNAs. RNA 19, 1632–1638 (2013).
Hunter, R. W. et al. Loss of Dis3l2 partially phenocopies Perlman syndrome in mice and results in up-regulation of Igf2 in nephron progenitor cells. Genes. Dev. 32, 903–908 (2018).
Chen, S. et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 238, 363–366 (1987).
Powell, L. M. et al. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 50, 831–840 (1987).
Rebagliati, M. R. & Melton, D. A. Antisense RNA injections in fertilized frog eggs reveal an RNA duplex unwinding activity. Cell 48, 599–605 (1987).
Bass, B. L. & Weintraub, H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 55, 1089–1098 (1988).
Bass, B. L. & Weintraub, H. A developmentally regulated activity that unwinds RNA duplexes. Cell 48, 607–613 (1987).
Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat. Rev. Mol. Cell Biol. 17, 83–96 (2016).
Herbert, A. ADAR and immune silencing in cancer. Trends Cancer 5, 272–282 (2019).
Chung, H. et al. Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell 172, 811–824.e14 (2018).
Ishizuka, J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43–48 (2019). In this study, ADAR1 depletion is shown to sensitize cells to immunotherapy and to prevent resistance, indicating that ADAR1 inhibition is a viable strategy to increase the efficacy of immunotherapies.
Weiss, S. A., Wolchok, J. D. & Sznol, M. Immunotherapy of melanoma: facts and hopes. Clin. Cancer Res. 25, 5191–5201 (2019).
Doroshow, D. B. et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin. Cancer Res. 25, 4592–4602 (2019).
Adams, S. et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 5, 1205–1214 (2019).
Chen, L. et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 19, 209–216 (2013).
Okugawa, Y. et al. Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer. J. Transl Med. 16, 366 (2018).
Shigeyasu, K. et al. AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. JCI Insight 3, 99976 (2018).
Chen, W. et al. A-to-I RNA editing of BLCAP lost the inhibition to STAT3 activation in cervical cancer. Oncotarget 8, 39417–39429 (2017).
Lazzari, E. et al. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat. Commun. 8, 1922 (2017).
Amin, E. M. et al. The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK. Sci. Signal. 10, eaah3941 (2017).
Zipeto, M. A. et al. ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis. Cell Stem Cell 19, 177–191 (2016).
Shoshan, E. et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat. Cell Biol. 17, 311–321 (2015).
Zhang, M. et al. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat. Commun. 9, 3919 (2018).
Galeano, F. et al. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. Oncogene 32, 998–1009 (2013).
Tomaselli, S. et al. Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. Genome Biol. 16, 5 (2015).
Wang, C. et al. Characterizing the role of PCDH9 in the regulation of glioma cell apoptosis and invasion. J. Mol. Neurosci. 52, 250–260 (2014).
Cesarini, V. et al. ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion. Nucleic Acids Res. 46, 2045–2059 (2018).
Kodama, T. et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am. J. Pathol. 165, 1743–1753 (2004).
Zhang, Y. et al. ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2Q607R. Cancer Cell Int. 18, 196 (2018).
Fu, L. et al. RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. Proc. Natl Acad. Sci. USA 114, E4631–E4640 (2017).
Chen, Y.-B. et al. ADAR2 functions as a tumor suppressor via editing IGFBP7 in esophageal squamous cell carcinoma. Int. J. Oncol. 50, 622–630 (2017).
Deng, W. et al. Trm9-catalyzed tRNA modifications regulate global protein expression by codon-biased translation. PLoS Genet. 11, e1005706 (2015).
Nedialkova, D. D. & Leidel, S. A. Optimization of codon translation rates via tRNA modifications maintains proteome integrity. Cell 161, 1606–1618 (2015).
Rapino, F., Delaunay, S., Zhou, Z., Chariot, A. & Close, P. tRNA modification: is cancer having a wobble? Trends Cancer 3, 249–252 (2017).
Rapino, F. et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature 558, 605–609 (2018). In this study, it is shown that U34 wobble-modifying enzymes are highly expressed in BRAF V600E-driven melanomas and their inhibition can restore sensitivity to BRAF inhibition in BRAF inhibitor-resistant melanomas.
Delaunay, S. et al. Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. J. Exp. Med. 213, 2503–2523 (2016).
Nguyen, A. et al. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression. Int. J. Oncol. 27, 949–956 (2005).
Ladang, A. et al. Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine. J. Exp. Med. 212, 2057–2075 (2015).
Schapira, M. Structural chemistry of human RNA methyltransferases. ACS Chem. Biol. 11, 575–582 (2016).
Wang, P., Doxtader, K. A. & Nam, Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol. Cell 63, 306–317 (2016).
Pugh, C. S., Borchardt, R. T. & Stone, H. O. Sinefungin, a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2’-)-methyltransferase, and viral multiplication. J. Biol. Chem. 253, 4075–4077 (1978).
Stein, E. M. et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131, 2662–2669 (2018).
Wang, L. et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat. Commun. 4, 2035 (2013).
Hashizume, R. et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med. 20, 1394–1396 (2014).
Véliz, E. A., Easterwood, L. H. M. & Beal, P. A. Substrate analogues for an RNA-editing adenosine deaminase: mechanistic investigation and inhibitor design. J. Am. Chem. Soc. 125, 10867–10876 (2003).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Wolpaw, A. J. & Dang, C. V. Exploiting metabolic vulnerabilities of cancer with precision and accuracy. Trends Cell Biol. 28, 201–212 (2018).
Rizos, H. et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20, 1965–1977 (2014).
Keith, G. Mobilities of modified ribonucleotides on two-dimensional cellulose thin-layer chromatography. Biochimie 77, 142–144 (1995).
Liu, N. et al. Probing N6-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA. RNA 19, 1848–1856 (2013).
Wetzel, C. & Limbach, P. A. Mass spectrometry of modified RNAs: recent developments. Analyst 141, 16–23 (2016).
Suzuki, T., Ueda, H., Okada, S. & Sakurai, M. Transcriptome-wide identification of adenosine-to-inosine editing using the ICE-seq method. Nat. Protoc. 10, 715–732 (2015).
Motorin, Y., Muller, S., Behm-Ansmant, I. & Branlant, C. Identification of modified residues in RNAs by reverse transcription-based methods. Methods Enzymol. 425, 21–53 (2007).
Edelheit, S., Schwartz, S., Mumbach, M. R., Wurtzel, O. & Sorek, R. Transcriptome-wide mapping of 5-methylcytidine RNA modifications in bacteria, archaea, and yeast reveals m5C within archaeal mRNAs. PLoS Genet. 9, e1003602 (2013).
Linder, B. et al. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat. Methods 12, 767–772 (2015).
Meyer, K. D. DART-seq: an antibody-free method for global m6A detection. Nat. Methods 16, 1275–1280 (2019).
Zhang, Z. et al. Single-base mapping of m6A by an antibody-independent method. Sci. Adv. 5, eaax0250 (2019).
Acknowledgements
The authors apologize to colleagues whose work was not acknowledged owing to space limitations. The authors thank A. Bannister for critically reading the manuscript and for the insightful discussions. Work in the Kouzarides laboratory is supported by grants from Cancer Research UK (grant reference RG17001) and the European Research Council (project number 268569), in addition to benefiting from core support from the Wellcome Trust (Core Grant reference 092096) and Cancer Research UK (grant reference C6946/A14492). I.B. is funded by a Kay Kendall Leukaemia Fund project grant (grant reference RG88664) and Cancer Research UK (grant reference RG86786).
Author information
Authors and Affiliations
Contributions
I.B. researched data for the article. T.K. contributed substantially to discussion of the content. I.B. and T.K contributed equally to writing the article and to reviewing and editing the manuscript.
Corresponding author
Ethics declarations
Competing interests
T.K. is a co-founder of Abcam and Storm Therapeutics, Cambridge, UK. I.B. declares no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Watson–Crick edge
-
The side of purine and pyrimidine bases involved in the canonical Watson–Crick base pairing.
- Cap
-
A characteristic structure of all eukaryotic mRNAs that consists of a N7-methylated guanine nucleotide bound to the first nucleotide of the mRNA via a 5′–5′ triphosphate bond.
- Primary miRNA
-
(pri-miRNA). Primary transcript from which one or several microRNAs originate. In many cases the same pri-miRNA can be a primary transcript for mRNA and other non-coding RNAs.
- Small nuclear RNA
-
(snRNA). A class of small non-coding RNA localized in the nucleus of eukaryotic cells as part of ribonucleoprotein complexes mediating mRNA maturation and splicing. They are functionally different from small nucleolar RNAs, which are involved in ribosome biogenesis.
- Hypomorphic mutations
-
Mutations partially impairing the function of the encoded protein.
- Enhancer RNA
-
(eRNA). Short (50–200 nucleotides) non-coding RNAs transcribed from enhancer regions and involved in transcriptional regulation both in cis (adjacent loci) and in trans (distant loci).
- Bisulfite sequencing
-
Technique making possible the mapping of 5-methylcytosine (m5C)-modified nucleotides within DNA or RNA. Cytosine nucleotides are converted into uracil on treatment with bisulfite, while methylated nucleotides are protected from this conversion. Methylation sites can then be detected by standard sequencing methods.
- Vault RNA
-
Vaults, large ribonucleoprotein particles in the cytoplasm isolated from higher eukaryotes, contain a small portion of small untranslated RNAs called vault RNAs. Vault RNA is transcribed by RNA polymerase II and, despite being part of the vault complex, does not have a structural role.
- Hoogsteen base pairing
-
A variation of base pairing in nucleic acids, formed by the interaction of the N7 position (as a hydrogen bond acceptor) and C6 amino group (as a donor) of a purine base, with the Watson–Crick (N3–C4) surface of a pyrimidine base.
- G-quadruplex structures
-
Formed in DNA and RNA molecules rich in guanines where four guanine bases can associate by Hoogsteen pairings to form a guanine tetrad, which in turn can stack on top of each other.
- Exonucleases
-
Enzymes removing single nucleotides from the ends of a DNA or RNA polynucleotide chain.
- Small nucleolar RNA
-
(snoRNA). A non-coding RNA localized in the nucleolus and part of ribonucleoprotein complexes involved in the modification of ribosomal RNA precursors and transfer RNAs.
- Precursor miRNA
-
(pre-miRNA). Hairpin intermediate precursors of microRNAs (miRNAs) produced by the cleavage of primary miRNAs by Drosha ribonuclease III (DROSHA) and microprocessor complex subunit DGCR8.
- Exoribonuclease
-
Enzyme that removes single nucleotides from the ends of an RNA polynucleotide chain.
- Wilms tumours
-
Rare kidney cancers affecting children.
- Transposable elements
-
Genomic elements capable of changing their position and copy numbers within the genome. DNA transposons do not go through an RNA intermediate, while retrotransposons are transcribed into an RNA intermediate and successively retrotranscribed to double-stranded DNA.
- Alu repeats
-
A type of genomic short interspersed element (SINE) representing the most common transposable element in the human genome with more than one million copies. They can influence gene expression and are involved in disease, including cancer.
- Seed sequence
-
Conserved heptameric region of a microRNA, typically positioned at the 5′ end determining target specificity (the binding of the microRNA to its target mRNA).
- Wobble position
-
The third base of a codon (or anticodon) characterized by promiscuous pairings. Modifications of this position on transfer RNAs allow non-Watson–Crick base pairing to occur and allow different codons to encode the same amino acid.
- Elongator complex
-
Multisubunit protein complex associated with RNA polymerase II and involved in 5-methoxycarbonylmethyl (mcm5) and 5-carbamoylmethyl (ncm5) modifications on uridines at wobble positions in transfer RNA and histone acetylation.
- Internal ribosome entry site
-
(IRES). RNA elements that allow internal cap-independent translation initiation. They are common in viral RNAs but are also found in stress-induced transcripts in eukaryotic cells.
- Rossmann fold
-
Structural motif commonly found in proteins that bind to nucleotides.
Rights and permissions
About this article
Cite this article
Barbieri, I., Kouzarides, T. Role of RNA modifications in cancer. Nat Rev Cancer 20, 303–322 (2020). https://doi.org/10.1038/s41568-020-0253-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-020-0253-2